Mode
Text Size
Log in / Sign up

Immunoglobulin A Nephropathy

Part of Nephritis

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Immunoglobulin A Nephropathy

4 trials tracked for Immunoglobulin A Nephropathy.

4Trials tracked
0Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 2 3 Phase 1 1
  1. Phase 2 Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade Completed
  2. Phase 2 A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN Completed
  3. Phase 2 Safety and Efficacy Study of VIS649 for IgA Nephropathy Completed
  4. Phase 1 First in Human Study to Assess Safety of VIS649 in Healthy Subjects Completed

Showing the 4 most-cited and recently-updated of 4 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Nephritis

Related studies from across the Nephritis family.

Sequential BTK inhibitor therapy maintains hematological and renal stability in Waldenström macroglobulinemia with renal dysfunction
Allergy & Immunology Meta-analysis
Sequential BTK inhibitor therapy maintains hematological and renal stability in Waldenström macroglobulinemia with renal dysfunction New treatment approach shows promise for rare blood cancer patients
This case report and systematic review describes a patient with Waldenström macroglobulinemia and light-chain proximal tubulopathy treated w…
A new treatment plan for a rare blood cancer helped a patient maintain stable kidney function and a steady blood response.
BAFF and APRIL signaling pathways drive pathogenic autoantibody production in IgA nephropathy and lupus nephritis
Rheumatology Sys. Review
BAFF and APRIL signaling pathways drive pathogenic autoantibody production in IgA nephropathy and lupus nephritis Biologic Therapies Target Specific Pathways in Kidney Diseases
This systematic review examines the role of BAFF and APRIL signaling pathways in IgA nephropathy, lupus nephritis, and primary membranous ne…
Newer biologic treatments are targeting specific immune pathways to manage conditions like IgA nephropathy and lupus nephritis.
Natural products like polysaccharides and TCM formulas may modulate gut microbiota to protect renal function
Nephrology Sys. Review
Natural products like polysaccharides and TCM formulas may modulate gut microbiota to protect renal function Natural Products May Help Manage Chronic Kidney Disease Symptoms
This systematic review examines the role of natural polysaccharides, traditional Chinese medicine formulas, and plant polyphenols in modulat…
Natural compounds like plant polyphenols may help protect the kidneys by improving gut health and reducing inflammation in patients with kid…
Telitacicept shows lower incidence of adverse drug reactions in patients with IgA nephropathy
Nephrology Meta-analysis
Telitacicept shows lower incidence of adverse drug reactions in patients with IgA nephropathy Telitacicept Shows Favorable Safety Profile for IgA Nephropathy
This meta-analysis of observational studies evaluated telitacicept monotherapy and combination therapy for IgA nephropathy. While no statist…
New data suggests telitacicept is a well-tolerated option for IgA nephropathy patients, showing fewer side effects than some other treatment…
Obinutuzumab achieves 86% overall clinical remission rate in refractory membranous nephropathy
Allergy & Immunology Meta-analysis
Obinutuzumab achieves 86% overall clinical remission rate in refractory membranous nephropathy Obinutuzumab shows promise for patients with hard to treat kidney disease
This meta-analysis evaluates the efficacy and safety of obinutuzumab for patients with refractory membranous nephropathy. The analysis repor…
A new treatment called obinutuzumab shows high remission rates for people with a rare, stubborn kidney condition known as membranous nephrop…
Mechanism-based strategies including CAR-T and bispecific engagers offer options for rituximab-resistant primary membranous nephropathy
Allergy & Immunology Sys. Review
Mechanism-based strategies including CAR-T and bispecific engagers offer options for rituximab-resistant primary membranous nephropathy New Strategies Target Treatment Resistance in Membranous Nephropathy
This systematic review examines the multifactorial mechanisms of rituximab resistance in patients with primary membranous nephropathy. It id…
Researchers identify new ways to treat primary membranous nephropathy when standard rituximab treatments do not work.
Wiskott-Aldrich syndrome with IgA nephropathy requires early recognition and multidisciplinary management
Pediatrics Sys. Review
Wiskott-Aldrich syndrome with IgA nephropathy requires early recognition and multidisciplinary management Kidney and immune issues linked to rare blood disorders in a boy
This narrative review and case presentation describes a 10-year-old boy with Wiskott-Aldrich syndrome/X-linked thrombocytopenia and IgA neph…
A 10-year-old boy with rare blood disorders developed kidney disease, showing how these conditions can affect multiple organs.
Meta-Analysis Reveals Shared Genetic Loci in Pediatric Nephrotic Syndrome and IgA Nephropathy
Psychiatry Meta-analysis
Meta-Analysis Reveals Shared Genetic Loci in Pediatric Nephrotic Syndrome and IgA Nephropathy Genetic clues link immune cells to pediatric kidney disease risks
A meta-analysis of GWAS data identified nine genome-wide significant loci for pediatric steroid-sensitive nephrotic syndrome and 19 pleiotro…
A large genetic analysis connects specific immune cell pathways to pediatric kidney conditions, offering new targets for future treatments.
Rituximab rechallenge caused severe hypersensitivity reaction in a patient with membranous nephropathy
Drug Pipeline Sys. Review
Rituximab rechallenge caused severe hypersensitivity reaction in a patient with membranous nephropathy A third Rituximab dose caused severe shock in a man with kidney disease
This case report describes a 52-year-old male with biopsy-proven primary membranous nephropathy who received a third 1 g infusion of rituxim…
A man with kidney disease developed life-threatening shock after a third Rituximab infusion, highlighting the need for careful monitoring an…
Telitacicept reduces proteinuria in adults with IgA nephropathy in Phase 3 trial
Drug Pipeline RCT
Telitacicept reduces proteinuria in adults with IgA nephropathy in Phase 3 trial New Drug Slashes Kidney Damage Risk in IgA Nephropathy Patients
This is an interim analysis of a Phase 3, multicenter, randomized, placebo-controlled trial in 318 adults with IgA nephropathy and persisten…
A targeted therapy reduced protein in urine by 55 percent more than placebo in people with IgA nephropathy, offering new hope for slowing ki…
Scoping review finds SGLT2 inhibitors show kidney protection in IgA nephropathy
Rheumatology RCT
Scoping review finds SGLT2 inhibitors show kidney protection in IgA nephropathy Two major trials show kidney-protective effects for a specific IgA nephropathy group
This scoping review synthesizes evidence on SGLT2 inhibitors in IgA nephropathy.
Two large trials found kidney-protective effects for some IgA nephropathy patients taking SGLT2 inhibitors, while real-world data showed red…
Narrative review discusses potential therapeutic roles of herbal compounds in membranous nephropathy
Urology Sys. Review
Narrative review discusses potential therapeutic roles of herbal compounds in membranous nephropathy Ancient Herbs Could Protect Kidneys From Autoimmune Damage
This narrative review explores the potential therapeutic roles of specific herbal compounds, including icariin and astragaloside IV, for mem…
Scientists are finding new ways to use natural plant compounds to protect damaged kidney filters.